KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial.

Yuankai Shi, Wei Guo, Wei Wang, Yunteng Wu, Meiyu Fang, Xiaoming Huang, Ping Han, Qingyuan Zhang, Pin Dong, Xiaohong Zhou, Hanwei Peng, Chunhong Hu, Xiaopin Chen, Shurong Zhang, Zhiwei Chang, Xiaojiang Li, Yuhai Ding, Song Qu, Shanghua Jing, Songnan Zhang, Lin Gui, Yan Sun, Lin Wang, Yanyan Liu, Hui Wu, Guoqing Li, Zhichao Fu, Jianhua Shi, Hao Jiang, Yuansong Bai, Jiuwei Cui, Yulong Zheng, Wei Cui, Xiaojing Jia, Limin Zhai, Qingqing Cai, Deming Xiong, Yunong Wu, Junning Cao, Rong Wu, Guangyuan Hu, Liang Peng, Liangzhi Xie, Wenlin Gai, Yan Wang, Yuehua Su

Nat Med 30(9) 2568-2575

PMID38942993
PMCID-
DOI10.1038/s41591-024-03110-7
发表日期2024-06-28
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

Immunotherapy combined with chemotherapy regimen has been shown to be effective in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, due to the small number of patients, its efficacy remains controversial in Asian populations, particularly in mainland China. Here a randomized, double-blind phase 3 trial evaluated the efficacy and safety of finotonlimab (SCT-I10A), a programmed cell death 1 (PD-1) monoclonal antibody, combined with cisplatin plus 5-fluorouracil (C5F) for the first-line treatment of R/M HNSCC. Eligible patients (n = 370) were randomly 2:1 assigned to receive finotonlimab plus C5F (n = 247) or placebo plus C5F (n = 123). The primary endpoint was overall survival (OS). In the finotonlimab plus C5F group, OS was 14.1 months (95% confidence interval (CI) 11.1-16.4), compared with 10.5 months (95% CI 8.1-11.8) in the placebo plus C5F group. The hazard ratio was 0.73 (95% CI 0.57-0.95, P = 0.0165), meeting the predefined superiority criteria for the primary endpoint. Finotonlimab plus C5F showed significant OS superiority compared with C5F alone and acceptable safety profile with R/M HNSCC, supporting its use as a first-line treatment option for R/M HNSCC. These results validate the efficacy and safety of the combination of finotonlimab and C5F in Asian patients with R/M HNSCC. ClinicalTrials.gov identifier: NCT04146402 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。